This article is more than 5 years old. Information may no longer be current.

Third group enrolled in phase 1/2 trial of achromatopsia treatment candidate

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Applied Genetic Technologies Corporation has completed enrollment in the third group of a dose escalation portion of a phase 1/2 trial of its subretinal injection achromatopsia treatment candidate, according to a press release.

AGTC is evaluating the safety and efficacy of rAAV2tYF-PR1.7-hCNGA3 in patients with achromatopsia (ACHM) caused by mutations in the CNGA3 gene. A parallel phase 1/2 trial is evaluating the company’s product candidates in ACHM caused by mutations in the CNGB3 gene.

“This achievement is another demonstration of our continued progress in the clinical development of our three product candidates for the treatment of X-linked retinitis pigmentosa and achromatopsia due to mutations in the CNGA3 or CNGB3 gene,” Sue Washer, president and CEO of AGTC, said in the release. “To date, we have dosed 68 patients across our orphan ophthalmology programs. This reflects the strong enthusiasm and support among patients and physicians for novel approaches to treating diseases that have tremendous unmet medical need.”

Interim dose escalation data from both trials are expected in the fourth quarter.